Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Bawor, Monica; Dennis, Brittany; Tan, Charlie; Pare, Guillaume; Varenbut, Michael; Daiter, Jeff; Plater, Carolyn; Worster, Andrew; Marsh, David; Steiner, Meir; Anglin, Rebecca; Desai, Dipika; Thabane, Lehana; Samaan, Zainab
• Is Part Of: Addiction science & clinical practice. Volume 10:Issue 1(2015)
• Page Start: 1
• Page End: 9
• Publication Date: 2015-12
• Subjects: Opioid use disorder -- Methadone maintenance treatment -- Treatment response -- BDNF -- Val66Met -- DRD2; Drug abuse -- Treatment -- United States -- Periodicals; Drugs -- Research -- United States -- Periodicals; Substance-Related Disorders -- therapy -- Periodicals; Pharmacetical Preparations -- Periodicals; 616.86005
• DOI: 10.1186/s13722-015-0040-7
• Languages: English
• ISSNs: 1940-0640

Abstract

Abstract Background The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward mechanisms is poorly understood, despite evidence suggesting their contribution to opioid use disorder. The aim of this study was to investigate the effect of brain-derived neurotrophic factor (BDNF ) and dopamine receptor D2 (DRD2 ) polymorphisms on continued opioid use among patients on methadone treatment for opioid use disorder. Methods BDNF 196G>A (rs6265 ) andDRD2 -241A>G (rs1799978 ) genetic variants were examined in patients with opioid use disorder who were recruited from methadone treatment clinics across Southern Ontario, Canada. We collected demographic information, substance use history, blood for genetic analysis, and urine to measure opioid use. We used regression analysis to examine the association between continued opioid use and genetic variants, adjusting for age, sex, ethnicity, methadone dose, duration in treatment, and number of urine screens. Results Among 240 patients treated with methadone for opioid use disorder, 36.3 percent (n = 87) and 11.3 percent (n = 27) had at least one risk allele forrs6265 andrs1799978, respectively. These genetic variants were not significantly associated with continued opioid use while on methadone maintenance treatment [rs6265 : odds ratio (OR) = 1.37, 95 % confidence interval (CI) = 0.792, 2.371, p = 0.264;rs1799978 : OR 1.27, 95 % CI 0.511, 3.182, p = 0.603]. Conclusions Despite an association ofBDNF rs6265 andDRD2 rs1799978 with addictive behaviors, these variants were not associated with continued illicit opioid use in patients treated with methadone. Problematic use of opioids throughout treatment with methadone may be attributed to nongenetic factors or a polygenic effect requiring further exploration. Additional research should focus on investigating these findings in larger samples and different populations.